To scroll text in this page

Global Navigation

Social Responsibility

Start of the main text

Reporting coverage, methods, etc.

Reporting Period

As a general rule, this Report covers the activities of facilities in Japan from April 1, 2015 to March 31, 2016, and the activities of overseas facilities from January 1, 2015 to December 31, 2015. (Certain sections of this Report contain details of activities and initiatives both prior to and after these identified reporting periods.)

Reporting Coverage

This report covers all places of business operated by consolidated subsidiaries of Astellas Pharma Inc. in Japan and all production facilities overseas as well as the principal places of business in Europe and the United States of America. However, the scope of reporting may differ depending in the item. Accordingly, details of the scope covered are identified on an individual basis in instances where a discrepancy arises.

In addition, certain environmental data includes the results of activities of subcontractors because the environment and society is affected not only by the Company's own activities but also via the supply chain.

Important Changes in Organization during the Reporting Period

The Kashima R&D Center closed at the end of fiscal 2015, and the operations of the Kiyosu Research Office were transferred to another company. However, the environmental performance track record of these two offices is included in this report. In August 2015, we opened the new Kyoto Suzaku Office, and its environmental performance track record in the current fiscal year has been included in the report.

Corporate Data

Company Name

Astellas Pharma Inc.

Headquarters

2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo 103-8411, Japan

Capital

¥103,001 million (as of March 31, 2015)

Representative Director

Yoshihiko Hatanaka (President and Chief Executive Officer)

Foundation

1923

Net Sales

1,372.7 billion (Consolidated basis, as of March 31, 2016)

Employees

17,217 (Consolidated basis, as of March 31, 2015)

Professional institution affiliation

Japan Business Federation
The Federation of Pharmaceutical Manufacturers' Associations of Japan
Japan Pharmaceutical Manufacturers Association, etc.

Scope of environmental information report

1.Coverage of the Environmental Action Plan

As a rule, applies to all business bases in Japan and all production bases overseas. The details of the facilities involved are as follows:

Company name Facility Location Function
Astellas Pharma Inc. Nihonbashi Office Chuo-ku, Tokyo Headquarters, Development
Takahagi Chemistry & Technology Development Center Takahagi, Ibaraki Research
Tsukuba Research Center Tsukuba, Ibaraki
Tsukuba Biotechnology Research Center Tsukuba, Ibaraki
Yaizu Pharmaceutical Research Center Yaizu, Shizuoka
Kiyosu Research Office Kiyosu, Aichi
Kashima R&D Center Yodogawa-ku, Osaka
Kyoto Suzaku Office Shimogyo-ku, Kyoto
Branches/Sales Offices 14 branches, 109 sales offices Sales & Marketing
Astellas Pharma Tech Co., Ltd. Nishine Plant Hachimantai, Iwate Manufacturing
Takahagi Technology Center Takahagi, Ibaraki
Yaizu Technology Center Yaizu, Shizuoka
Toyama Technology Center Toyama, Toyama
Takaoka Plant Takaoka, Toyama
Astellas Pharma Technologies Inc. Norman Plant U.S.A
Astellas Ireland Co., Ltd. Dublin Plant Ireland
Kerry Plant
Astellas Pharma Europe B.V. Meppel Plant Netherlands
Astellas Pharma China, Inc. Shenyang Plant China

Note 1) Operating sites throughout this report are in principle identified according to the name of each facility. In instances where there are multiple facilities on the same site, the following names may be applied.

  • Takahagi Facilities (Takahagi Chemistry & Technology Development Center and Takahagi Technology Center)
  • Yaizu Facilities (Yaizu Pharmaceutical Research Center and Yaizu Technology Center)

2. Facilities Outside the Coverage of Environmental Action Plan

Principal office buildings and research R&D Centers operated by the consolidated subsidiaries listed below:

  • Astellas US LLC (U.S.A.)
  • Astellas Pharma Europe Ltd. (U.K.)
  • Astellas Pharma Europe B.V. (Netherlands)
  • Agensys, Inc. (U.S.A.)
  • Astellas Research Institute of America LLC (U.S.A.)

And office buildings used by sales companies in the Americas, EMEA (Europe, the Middle East and Africa including NIS countries), and the Asia and Oceania regions


Methods for Calculating Performance Data

Methods for Calculating Energy Consumption and GHGs

Type Conversion Coefficients
Calorific value CO2 emissions
Electricity 9.97 GJ/MWh 0.570 tons/MWh *1
Fuel oil 39.1 GJ/kiloliter 2.71 tons/kiloliter
Kerosene 36.7 GJ/kiloliter 2.49 tons/kiloliter
LPG 50.8 GJ/ton 3.00 tons/ton
LNG 54.6 GJ/ton 2.70 tons/ton
City gas 45.0 GJ/thousand m3N 2.24 tons/thousand m3N
Diesel oil 37.7 GJ/kiloliter 2.58 tons/kL
Gasoline 34.6 GJ/kiloliter 2.32 tons/kL
Purchased thermal energy 1.36 GJ/GJ 0.057 tons/GJ
  Electricity *2 Steam
Norman Plant 0.489 tons/MWh -
Dublin Plant,
Kerry Plant
0.435 tons/MWh -
Meppel Plant 0.452 tons/MWh -
Shenyang Plant 0.711 tons/MWh 0.091 tons/GJ
  1. *1 For CO2 emissions calculations in fiscal 2015, we have used the coefficient for fiscal 2014, because at the time of the release (June 2015) of our Japanese Environmental Report, FEPC's latest CO2 emission coefficient was unavailable.
  2. *2 See the CO2 emission coefficient accompanying the end-use electricity under Measures to Address Climate Change.
  3. *3 In converting the amount of power generated by renewable energy sources such as solar and wind into energy value in Joule, we have used a conversion rate of 3.6 MJ per 1 kWh.

Calculation Method for Scope 3 Emissions

Main Text end
Local Navigation
Local Navigation end
Related Links